(Q43662609)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11438417%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11438417%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

0 references

1 reference

chronic lymphocytic leukemia

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11438417%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Sylvie Chevret

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11438417%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Vincent Levy

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11438417%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

author name string

F Delabarre

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11438417%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

M Leporrier

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11438417%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

B Cazin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11438417%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

French Cooperative CLL Group

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11438417%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 July 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11438417%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Epidemiology

9 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11438417%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11438417%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11438417%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

747-754

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11438417%20AND%20SRC:MED&resulttype=core&format=json

Chronic lymphocytic leukemia

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

Absence of minimal residual disease detectable by FACS, Southern blot or PCR in patients with chronic lymphocytic leukaemia treated with fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

Quality adjusted survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

The duration of a life of quality should become the focus of "quality-of-life" studies

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. International Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

Quality-of-life-adjusted survival for comparing cancer treatments. A commentary on TWiST and Q-TWiST.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

Measuring patient-centered outcomes in neurologic disease. Extending the Q-TWiST method.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: A Q-TWiST analysis of the Pediatric Oncology Group Study 8821.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900359-0

7 January 2021

10.1016/S0895-4356(00)00359-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11438417%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference